CA2300813A1 - Agent antiinflammatoire - Google Patents

Agent antiinflammatoire Download PDF

Info

Publication number
CA2300813A1
CA2300813A1 CA002300813A CA2300813A CA2300813A1 CA 2300813 A1 CA2300813 A1 CA 2300813A1 CA 002300813 A CA002300813 A CA 002300813A CA 2300813 A CA2300813 A CA 2300813A CA 2300813 A1 CA2300813 A1 CA 2300813A1
Authority
CA
Canada
Prior art keywords
group
inflammatory agent
groups
compound
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002300813A
Other languages
English (en)
Inventor
Hiroyuki Odaka
Yu Momose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2300813A1 publication Critical patent/CA2300813A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings

Abstract

L'invention concerne un agent anti-inflammatoire qui modifie, par une action inhibant TNF-.alpha. et qui comprend un composé de formule (I), dans laquelle R représente un groupe hydrocarbure qui peut être substitué ou un groupe hétérocyclique qui peut être substitué; Y représente un groupe de formule -CO-, CH(OH)-, ou -NR?3¿-, R?3¿ représentant un groupe alkyle qui peut être substitué; m vaut 0 ou 1; n vaut 0, 1 ou 2; X représente CH ou N; A représente une liaison chimique ou un groupe hydrocarbure aliphatique ayant 1 à 7 atomes de carbone; Q représente oxygène ou soufre; R?1¿ représente hydrogène ou un groupe alkyle; le cycle E peut comporter de plus 1 à 4 substituants, qui peuvent former un cycle en combinaison avec R?1¿; L et M représentent respectivement hydrogène ou peuvent être combinés l'un à l'autre pour former une liaison chimique; ou un sel de celui-ci.
CA002300813A 1997-08-21 1998-08-20 Agent antiinflammatoire Abandoned CA2300813A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP9/225302 1997-08-21
JP22530297 1997-08-21
PCT/JP1998/003692 WO1999009965A2 (fr) 1997-08-21 1998-08-20 Agent antiinflammatoire

Publications (1)

Publication Number Publication Date
CA2300813A1 true CA2300813A1 (fr) 1999-03-04

Family

ID=16827222

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002300813A Abandoned CA2300813A1 (fr) 1997-08-21 1998-08-20 Agent antiinflammatoire

Country Status (4)

Country Link
EP (1) EP1007038A2 (fr)
AU (1) AU8747998A (fr)
CA (1) CA2300813A1 (fr)
WO (1) WO1999009965A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2248107T3 (es) * 1999-08-31 2006-03-16 Incyte San Diego Incorporated Benciliden-tiazolidindionas y analogos y su utilizacion en el tratamiento de la diabetes.
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US20030060488A1 (en) * 2000-02-10 2003-03-27 Yasuo Sugiyama Drug comprising combination
WO2001062238A2 (fr) * 2000-02-24 2001-08-30 San Diego State University Procede servant a traiter des maladies du foie associees a la fonction hepatique
MXPA03008117A (es) 2001-03-07 2004-11-12 Incyte San Diego Inc Derivados heterociclicos para el tratamiento del cancer y otras enfermedades proliferativas.
AU2002254171A2 (en) 2001-03-08 2002-09-24 Incyte San Diego, Inc. RXR activating molecules
DE122010000047I1 (de) 2001-06-26 2011-05-05 Amgen Fremont Inc Antikörper gegen opgl
US7071218B2 (en) 2001-11-15 2006-07-04 Incyte San Diego Incorporated N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases
GB0128138D0 (en) * 2001-11-23 2002-01-16 King S College London Pharmaceutical use
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US8915253B2 (en) 2005-07-18 2014-12-23 Tearscience, Inc. Method and apparatus for treating gland dysfunction employing heated medium
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
WO2008027069A1 (fr) 2006-08-21 2008-03-06 Tearscience, Inc. Procédé et appareil de traitement du dysfonctionnement de la glande de meibomius au moyen d'un fluide
ES2942724T3 (es) 2013-04-30 2023-06-06 Alcon Inc Sistemas para el tratamiento de enfermedades del ojo
US9763827B2 (en) 2013-04-30 2017-09-19 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
US10974063B2 (en) 2016-06-30 2021-04-13 Alcon Inc. Light therapy for eyelash growth

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
ZA961081B (en) * 1995-02-10 1996-10-15 Schering Ag Pharmaceutical preparations for tnf inhibition
JPH11511004A (ja) * 1995-05-04 1999-09-28 シティ・オブ・ホープ ヒト白血球１２−リポキシゲナーゼおよび疾病状態の病因でのその役割
DE19540475A1 (de) * 1995-10-20 1997-04-24 Schering Ag Chirale Methylphenyloxazolidinone
DE69713890T3 (de) * 1996-04-05 2006-09-07 Takeda Pharmaceutical Co. Ltd. Pharmazeutische kombination enthaltend einen wirkstoff mit angiotensin-ii antagonistischer aktivität und einen wirkstoff der die insulin-sensitivität erhöht
EP0953355A4 (fr) * 1996-05-31 2002-02-27 Sankyo Co Remede pour maladies auto-immunes

Also Published As

Publication number Publication date
WO1999009965A2 (fr) 1999-03-04
EP1007038A2 (fr) 2000-06-14
AU8747998A (en) 1999-03-16
WO1999009965A3 (fr) 1999-05-20

Similar Documents

Publication Publication Date Title
US6087384A (en) Apoptosis inhibitor
EP1093370B1 (fr) Composition pharmaceutique pour le traitement du diabete
JP3148973B2 (ja) 医 薬
CA2300813A1 (fr) Agent antiinflammatoire
US6365607B1 (en) Anticachectic composition
CA2247946C (fr) Composition anticachexique
JP4473355B2 (ja) アポトーシス抑制剤
JPH11124331A (ja) 抗炎症剤
KR20020063555A (ko) 약학 조성물
JP2008201800A (ja) 悪液質の予防・治療剤
MXPA00010582A (en) Pharmaceutical composition for the treatment of diabetes
JP2001294537A (ja) 併用医薬
JP2003012551A (ja) Ａｂｃ発現促進剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued